 AbCellera stock has continued to struggle of late given the absolutely terrible sentiment in the biotech market, however the companys actual business is thriving under the surface. In the Q1 earnings call, the company highlighted both the internally developed T-Cell engager platform, along with the Empirico deal which provides the option to co-invest in programs. 